Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis (MS), has today announced that leading NonTuberculous Mycobacterium (NTM) research scientist, Dr. Rahul Narang, will be showcasing the Designer Diagnostics test kit technology in an upcoming presentation at the 38th Union World Conference on Lung Health in South Africa. Designer Diagnostics is a wholly-owned subsidiary of Nutra Pharma Corp.
"It's an honor to have such a well-respected scientist showcase our technology at one of the largest international conferences on lung health," commented Neil Roth, President of Designer Diagnostics. "We believe that Dr. Narang's presentation will help build awareness about the health concerns surrounding NTM, especially in patients living with AIDS," he concluded.
The Conference, which is hosted by the International Union Against Tuberculosis and Lung Disease (The Union), will take place from November 8th through November 12th, 2007. This year's conference theme is "Confronting the challenges of HIV and MDR in TB prevention and care."
"The Designer Diagnostics test kits were used to isolate NTM from clinical samples of 300 AIDS patients and for the first time ever on the Indian subcontinent, we successfully isolated M. wolinskyi in clinical samples," explained Dr. Rahul Narang. "In addition, these test kits were also used for the first time to isolate NTM from soil and water samples collected from the environment of patients with NTM disease," he added.
"The timing for this presentation is ideal, as we are currently working with National Jewish Medical and Research Center in Denver, Colorado, to complete third party validation of our test kits," explained Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. "This validation is the final step needed in bringing our test kits to market," he concluded.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's holding, ReceptoPharm, Inc, is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
http://www.NutraPharma.com
http://www.DesignerDiagnostics.com
SEC Disclaimer
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The conference presentation should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
